Transgenically produced antithrombin III
US7928064B2 · kind B2 · utility
6Cited by
7References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2005 |
| Grant date | Apr 19, 2011 |
| Priority date | — |
| Expiry date | Sep 2, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/832
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.